Janus Henderson Group PLC purchased a new stake in shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) in the second quarter, according to its most recent 13F filing with the SEC. The fund purchased 558,815 shares of the company’s stock, valued at approximately $21,989,000. Janus Henderson Group PLC owned approximately 1.49% of Deciphera Pharmaceuticals at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DCPH. SG Americas Securities LLC purchased a new position in shares of Deciphera Pharmaceuticals during the 1st quarter valued at $152,000. New York State Common Retirement Fund grew its position in Deciphera Pharmaceuticals by 37.5% in the first quarter. New York State Common Retirement Fund now owns 9,900 shares of the company’s stock worth $198,000 after acquiring an additional 2,700 shares in the last quarter. Trexquant Investment LP purchased a new position in Deciphera Pharmaceuticals in the second quarter worth $203,000. Rhumbline Advisers purchased a new position in Deciphera Pharmaceuticals in the second quarter worth $301,000. Finally, Deutsche Bank AG purchased a new position in Deciphera Pharmaceuticals in the fourth quarter worth $410,000. Hedge funds and other institutional investors own 53.49% of the company’s stock.
NASDAQ DCPH opened at $36.45 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 18.44 and a current ratio of 18.44. Deciphera Pharmaceuticals Inc has a 12-month low of $15.15 and a 12-month high of $45.61.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.03. equities analysts forecast that Deciphera Pharmaceuticals Inc will post -2.59 EPS for the current year.
Several research analysts recently issued reports on DCPH shares. JPMorgan Chase & Co. upped their target price on shares of Deciphera Pharmaceuticals from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Monday, June 4th. SunTrust Banks started coverage on shares of Deciphera Pharmaceuticals in a research report on Thursday, July 5th. They issued a “buy” rating for the company. Cantor Fitzgerald started coverage on shares of Deciphera Pharmaceuticals in a research report on Wednesday, August 22nd. They issued an “overweight” rating and a $53.00 target price for the company. JMP Securities upped their target price on shares of Deciphera Pharmaceuticals to $65.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 19th. Finally, Canaccord Genuity set a $55.00 target price on shares of Deciphera Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 13th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Deciphera Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $50.10.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Read More: Dividend
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.